MB-CART19.1

N/A

Report date: 2024/07/10 16:25:18

Base Information

Drug NameMB-CART19.1
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsAnti-CD20T lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsCentral Nervous System LymphomaScleroderma, SystemicLupus Erythematosus, Systemic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMiltenyi Biomedicine Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Erlangen-Nuremberg Medical SchoolMiltenyi Biomedicine Gmbh
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaScleroderma, SystemicLupus Erythematosus, Systemic +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A